Trial
NCT02781506
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Texas Southwestern Medical Center
Collaborators
—
Condition
Metastatic Clear Cell Renal Cell Carcinoma
Intervention
Nivolumab
Why stopped
Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming eligible for this trial and therefore, the trial was terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-08